Critical Reviews in Oncology Hematology Critical Reviews in Oncology Hematology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions
The median overall survival of patients with GBM remains inferior to 15  months and nearly all patients recur eventually: in the long term follow-up of patients included in the European Organization for Research and Treatment of Cancer (EORTC)/ National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) trial (Stupp et al., 2005), only 6% were progression-fre e at 3 years (Stupp et al., 2009). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Silvia Scoccianti, Giulio Francolini, Giulio Alberto Carta, Daniela Greto, Beatrice Detti, Gabriele Simontacchi, Luca Visani, Muhammed Baki, Linda Poggesi, Pierluigi Bonomo, Monica Mangoni, Isacco Desideri, Stefania Pallotta, Lorenzo Livi Source Type: research

Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – Not an innocent bystander
Endogenous glucocorticoids are steroidal hormones essential to sustaining human life. Synthetic glucocorticoids have been utilized for medicinal purposes for over 70 years (Kadmiel and Cidlowski, 2013), first prescribed for the treatment of rheumatoid arthritis. Glucocorticoids were first used for the treatment of cancer as part of the treatment protocol of leukemia. They were later used for the treatment of many hematological malignancies due to their ability to mediate apoptosis in leukemia, lymphoma and myeloma cells (Greenstein et al., 2002; Frankfurt and Rosen, 2004). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Corinne Maurice-Dror, Ruth Perets, Gil Bar-Sela Source Type: research

Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis
To improve the accuracy of chemoradiation therapy in anal cancer patients PET/CT is frequently used in the planning of radiation therapy. A systematic review was performed to assess impact on survival, quality of life, symptom score, change in target definition and treatment intention. Systematic literature searches were conducted in Medline, EMBASE, the Cochrane Library, and Centre for Reviews and Dissemination. Ten cross-sectional studies were identified. No data were available on survival or quality of life. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Per Albertsson, Charlotte Alverbratt, Ann Liljegren, Emil Bj örkander, Annika Strandell, Ola Samuelsson, Stig Palm, Andreas Hallqvist Source Type: research

Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review
To provide an overview of prediction models for the risk of developing endometrial cancer in women of the general population or for the presence of endometrial cancer in symptomatic women. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Maaike Alblas, Kimberley B. Velt, Nora Pashayan, Martin Widschwendter, Ewout W. Steyerberg, Yvonne Vergouwe Source Type: research

Re-irradiation as salvage treatment in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions
The median overall survival of patients with GBM remains inferior to 15  months and nearly all patients recur eventually: in the long term, follow-up of patients included in the European Organization for Research and Treatment of Cancer (EORTC)/ National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) trial (Stupp et al.,2005), only 6% were progression-fre e at 3 years (Stupp et al., 2009). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Silvia Scoccianti, Giulio Francolini, Giulio Alberto Carta, Daniela Greto, Beatrice Detti, Gabriele Simontacchi, Luca Visani, Muhammed Baki, Linda Poggesi, Pierluigi Bonomo, Monica Mangoni, Isacco Desideri, Stefania Pallotta, Lorenzo Livi Source Type: research

Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – not an innocent bystander
Endogenous glucocorticoids are steroidal hormones essential to sustaining human life. Synthetic glucocorticoids have been utilized for medicinal purposes for over 70 years (Kadmiel and Cidlowski, 2013), first prescribed for the treatment of rheumatoid arthritis. Glucocorticoids were first used for the treatment of cancer as part of the treatment protocol of leukemia. They were later used for the treatment of many hematological malignancies due to their ability to mediate apoptosis in leukemia, lymphoma and myeloma cells (Greenstein et al., 2002; Frankfurt and Rosen, 2004). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Corinne Maurice-Dror, Ruth Perets, Gil Bar-Sela Source Type: research

Positron Emission Tomography and Computed Tomographic (PET/CT) Imaging for Radiation Therapy Planning in Anal Cancer: a Systematic Review and Meta-analysis
To improve the accuracy of chemoradiation therapy in anal cancer patients PET/CT is frequently used in the planning of radiation therapy. A systematic review was performed to assess impact on survival, quality of life, symptom score, change in target definition and treatment intention. Systematic literature searches were conducted in Medline, EMBASE, the Cochrane Library, and Centre for Reviews and Dissemination. Ten cross-sectional studies were identified. No data were available on survival or quality of life. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Per Albertsson, Charlotte Alverbratt, Ann Liljegren, Emil Bj örkander, Annika Strandell, Ola Samuelsson, Stig Palm, Andreas Hallqvist Source Type: research

Prediction models for endometrial cancer for the general population or symptomatic women: a systematic review
To provide an overview of prediction models for the risk of developing endometrial cancer in women of the general population or for the presence of endometrial cancer in symptomatic women. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Maaike Alblas, Kimberley Velt, Nora Pashayan, Martin Widschwendter, Ewout Steyerberg, Yvonne Vergouwe Source Type: research

Role of bevacizumab in uterine leiomyosarcoma
In the recent years, angiogenetic inhibitors have emerged for the treatment of several malignancies. In particular, bevacizumab has proved to be effective in many types of cancers (including sarcoma), but the limitations of antiangiogenic therapy have been shown in practice. Here, we sought to review the current evidence on the role and efficacy of bevacizumab in patients affected by uterine leiomyosarcoma. On April 2017, Literature was searched in order to identify studies reporting outcomes of patients affected either by early stage or advanced/recurred uterine leiomyosarcoma undergoing treatment with bevacizumab, alone ...
Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Giorgio Bogani, Antonino Ditto, Fabio Martineli, Mauro Signorelli, Valentina Chiappa, Caterina Fonatella, Roberta Sanfilippo, Umberto Leone Roberti Maggiore, Simone Ferrero, Domenica Lorusso, Francesco Raspagliesi Source Type: research

Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system
Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic, hypertensive, cardiomyopathic, and arrhythmic complications can present as a significant challenge for clinicians treating cancer patients. If early diagnosis and intervention of cardiotoxic complications is missed, this can lead to delay or abrogation of planned treatment, which can potentially culminate to significant morbidity due to not only the cardiotoxic complications but also the progression of cancer. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Hani M Babiker, Ali McBride, Michael Newton, Leigh M. Boehmer, Adrienne Goeller Drucker, Mollie Gowan, Manouchkathe Cassagnol, Todd D. Camenisch, Faiz Anwer, James M. Hollands Source Type: research

Clinical importance of DNA repair in sporadic colorectal cancer
Colorectal cancer (CRC) is the third major cause of cancer-related deaths worldwide. However, despite the scientific efforts to provide a molecular classification to improve CRC clinical practice management, prognosis and therapeutic decision are still strongly dependent on the TNM staging system. Mismatch repair system deficiencies can occur in many organs, but it is mainly a hallmark of CRC influencing clinical outcomes and response to therapy. This review will discuss the effect of the modulation of other DNA repair pathways (direct, excision and double strand break repairs) in the clinical and pathological aspects of c...
Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Gustavo A. Laporte, Natalia M. Leguisamo, Antonio N. Kalil, Jenifer Saffi Source Type: research

Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
This article discusses these findings and their implications for clinical practice. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Evangelos Terpos, Florence Suzan, Hartmut Goldschmidt Source Type: research

Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms
To review published nomograms that predict endpoints such as overall survival (OS) or risk of intracranial relapse in patients with brain metastases from solid tumors. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Carsten Nieder, Minesh P. Mehta, Hans Geinitz, Anca L. Grosu Source Type: research

Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is a hematological malignancy which is characterized by progressive accumulation of functionally deficient B cells in blood, bone marrow, and lymphatic tissue. The tumor microenvironment (TME) appears to play a critical role in genesis and progression of CLL. High levels of extracellular adenosine (ADO) are detected in CLL as a consequence of expression of ecto-enzymes, such as CD39 and CD73. Extracellular ADO exhibits a broad range of effects on cell cycle control, immunoregulation, angiogenesis and cytokine regulation through both direct and indirect mechanisms. (Source: Critical Review...
Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Yiqing Cai, Lili Feng, Xin Wang Source Type: research

Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology
Following the establishment of cytogenetics as well as “traditional” molecular techniques (PCR, fluorescent-based molecular methods such as real-time PCR, and Sanger sequencing) within the last four to five decades, a multitude of genetic alterations have been identified to be typical and crucial for distinct hematologic entities, like t(9;22)(q34;q 11)/BCR-ABL1 in chronic myeloid leukemia (CML) or t(15;17)/PML-RARA in acute promyelocytic leukemia (APL), and became relevant for diagnosis, classification, prognostication and therapeutic planning in hematologic and solid malignancies. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Evgenii Shumilov, Johanna Flach, Thomas Pabst, Martin Fiedler, Anne Angelillo-Scherrer, Lorenz Tr ümper, Raphael Joncourt, Alexander Kohlmann, Ulrike Bacher Source Type: research